Validation of the <scp>OMNI</scp> vocal effort scale in the treatment of adductor spasmodic dysphonia

Shoffel‐Havakuk, Hagit; Marks, Katherine L.; Morton, Mariah; Johns, Michael M.; Hapner, Edie R.

doi:10.1002/lary.27430

Cited by 22 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It found that although QOL had improved for ADLD patients undergoing BoNT-A treatment, they still spend a significant proportion of each treatment cycle with a reduced QOL [123]. Shoffel-Havakuk et al [124] established the validity of the OMNI Vocal Effort Scale (OMNI-VES) for rating perceived voice-rating perception in patients with ADLD and concluded that it could be used to evaluate response for BoNT-A injection treatment. Interestingly, only a weak correlation was found between the OMNI-VES and the more widely circulated Voice-Related Quality of Life (V-RQOL) scores in a case group of 178 patients.…”

Section: Assessment Of Treatment Outcomesmentioning

confidence: 99%

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Yeung

Richards

Novakovic

2022

Toxins

View full text Add to dashboard Cite

Laryngeal dystonia (LD), or spasmodic dysphonia (SD), is a chronic, task-specific, focal movement disorder affecting the larynx. It interferes primarily with the essential functions of phonation and speech. LD affects patients’ ability to communicate effectively and significantly diminishes their quality of life. Botulinum neurotoxin was first used as a therapeutic agent in the treatment of LD four decades ago and remains the standard of care for the treatment of LD. This article provides an overview of the clinical application of botulinum neurotoxin in the management of LD, focusing on the classification for this disorder, its pathophysiology, clinical assessment and diagnosis, the role of laryngeal electromyography and a summary of therapeutic injection techniques, including a comprehensive description of various procedural approaches, recommendations for injection sites and dosage considerations.

show abstract

Section: Assessment Of Treatment Outcomesmentioning

confidence: 99%

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Yeung

Richards

Novakovic

2022

Toxins

View full text Add to dashboard Cite

show abstract

“…Voice assessment was performed during 4 different stimulation settings: left thalamic stimulation only, right thalamic stimulation only, bilateral stimulation, and no stimulation. For each setting, a patient perception test (OMNI -Vocal Effort Scale (OMNI-VES) [7]) and an investigator perception test (Unified Spasmodic Dysphonia Rating Scale (USDRS) [8]) were used. All voice testing was performed in a double-blinded fashion.…”

Section: Voice Assessmentmentioning

confidence: 99%

“…The OMNI-VES is a validated patient perception test for rating of voice-related perceived exertion in patients with SD. It is a simple single question test with a scale ranging from 0 to 10 [7]. All patients scored their voices in a blinded fashion.…”

Section: Omni -Vocal Effort Scalementioning

confidence: 99%

“…In order to investigate the success of any treatment, reliable tests measuring the outcome are required. Many studies evaluating the effects of laryngeal botulinum toxin A (Botox) injections on SD symptoms have reported a poor correlation between the subjective benefit experienced by patients and the objective vocal scores measured by investigators [7,25,26]. This may be due to the beneficial effect of treatment on vocal effort or strain, which is difficult for an external examiner to evaluate but is immediately obvious to the patient.…”

Section: What Test Best Measures Sd?mentioning

confidence: 99%

See 1 more Smart Citation

Deep Brain Stimulation for Spasmodic Dysphonia: A Blinded Comparison of Unilateral and Bilateral Stimulation in Two Patients

Krüger

Honey

2020

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Deep brain stimulation (DBS) is a promising new therapy for patients with spasmodic dysphonia (SD). The preliminary results from our randomized controlled trial showed good clinical effects with unilateral left thalamic stimulation in 6 righthanded patients. This suggests that the pathological process underpinning SD may have a "hemisphere dominant" pathway. We describe 2 patients with concurrent essential tremor and SD who had previously undergone bilateral thalamic DBS for their limb tremor. Both patients experienced an unanticipated improvement of their SD symptoms. One patient was right-handed, and the other was mixed left-handed. To investigate the amount of SD improvement following DBS therapy in each hemisphere, 4 different settings were tested: both sides on, left side on, right side on, and both sides off. Both patients most improved following bilateral stimulation. There was, however, a powerful unilateral benefit in both patients with only a small additional benefit from bilateral stimulation. The right-handed patient improved most with left-hemisphere stimulation whereas the mixed left-handed patient improved most with right hemisphere stimulation. There was some discrepancy between the two tests applied in the second patient reflecting the known difficulties to evaluate vocal symptom improvement in SD. We discuss the possible correlation of handedness and speech hemisphere dominance as well as the need for more reliable tests to measure SD severity. Ultimately, we recommend a bilateral approach for future studies, using a patient perception test as the primary outcome and functional imaging to further investigate the correlation of handedness and the amount of hemisphere dominance in SD.

show abstract

“…23 The OMNI-VES is a singlequestion and easily understood scale with reported ease of completion and high responsiveness. 22 The CPIB and its General Short Form (CPIB-10), allows respondents to rate the extent their communication disorder interferes in various situations on a 4-point Likert scale. 23,24 The objective of this study was twofold.…”

Section: Introductionmentioning

confidence: 99%

Exploring Patient's Preference of Patient‐Reported Outcome Measures in Laryngeal Movement Disorders

et al. 2022

View full text Add to dashboard Cite

Background: Despite many available patient-reported outcome measures (PROMs) for laryngeal movement disorders, there is a lack of patient input regarding which PROM most accurately and conveniently captures aspects related to their vocal disease. This study aimed to assess patients' preferences among a selection of voice-related PROMs (Voice Handicap Index-10 [VHI-10], OMNI-Vocal Effort Scale [OMNI-VES], Communicative Participation Item Bank-General Short Form [CPIB-10], and Visual Analog Scales [VAS]) within the laryngeal movement disorder population and investigate associations between selected instruments.Methods: Prior to botulinum toxin A injection, patients with laryngeal dystonia and/or essential tremor of the vocal tract were administered the VHI-10, OMNI-VES, CPIB-10, and three novel VAS questions in a randomized order. Patients rank ordered the four PROMs based on the PROMs' reflection of their voice problems. Pearson's correlation coefficients evaluated pairwise associations among PROM scores. Fisher's exact test compared the preferred PROM rankings.Results: Seventy patients (53 female, mean age = 60.7 years) participated. The VHI-10 and CPIB-10 were most preferred at 33.9% and 27.4% respectively. The OMNI-VES and VAS scales were less favored (19.4%, each). When analyzed by age ≥60 years, the CPIB-10 was most favored (33.3%), but for age <60 years, VHI-10 was most preferred (42.3%). There was a strong correlation between scores of all administered PROMs (strongest correlation between OMNI-VES and VAS, r = 0.8, p < 0.001; the weakest correlation between OMNI-VES and VHI-10, r = 0.6, p < 0.001).Conclusions: With an increasing trend in PROMs usage and a strong correlation between all evaluated outcome instruments, insight regarding patients' PROM preferences is an area for further consideration.

show abstract

Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia

Cited by 22 publications

References 40 publications

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

Deep Brain Stimulation for Spasmodic Dysphonia: A Blinded Comparison of Unilateral and Bilateral Stimulation in Two Patients

Exploring Patient's Preference of Patient‐Reported Outcome Measures in Laryngeal Movement Disorders

Contact Info

Product

Resources

About